The information of Preventing with Experts' pipeline is only aimed at veterinary medical professionals.
Are you a health professional?

BRUCELLOSIS

The best prophylactic tool to control the disease in endemic areas through mass vaccination programs

THE VACCINE OF CHOICE AGAINST BOVINE BRUCELLOSIS

In addition to its high zoonotic impact, Brucellosis is a major cause of abortion and infertility in cattle, which results in significant economic losses for farmers. Vaccination is the most practical and effective tool to reduce the incidence of brucellosis in endemic areas.

B19 CZV OCULAR is a freeze-dried suspension of the live Brucella abortus strain 19 vaccine (also called B-19 strain) in the smooth phase for the immunization of cattle against Brucellosis induced either by Brucella abortus or Brucella melitensis.

Manufactured in compliance with OIE and EU standards, B19 CZV OCULAR is the first anti-brucellosis vaccine registered for conjunctival administration to cattle.

Moreover, B19 CZV OCULAR is safe enough even in adult cows, being the best prophylactic tool to control the disease in endemic areas through mass vaccination programs. When applied in young replacement heifers and combined with suitable diagnostic methods, it can be used successfully in test and slaughter-based eradication programs.

EXPERT´S OPINION

Is the best prophylactic tool to control the disease in endemic areas through mass vaccination programs.

PRECISE DOSE

B19 CZV OCULAR combines a perfect dissolution of the freeze-dried content with a suitable solvent (stained with Patent Blue V to allow better assessment of the proper application in the conjunctival mucosa) and the high dosage precision of the dropper, allowing easy vaccine application as a single drop placed on the corneal surface.

Beef cattle: application of the B19 CZV Ocular

Dairy cattle: application of the B19 CZV Ocular

Vaccine administration video

THE MOST PRACTICAL TOOL TO CONTROL BOVINE BRUCELLOSIS

When the objective is to reduce brucellosis prevalence to a minimum, B19 CZV OCULAR is the vaccine of choice for mass vaccination since:

A single dose confers suitable immunity in a similar way to that induced by the classical subcutaneous vaccine.

With the exception of bulls (in which safety has not been fully assessed), it can be used in both young and adult animals, including pregnant and lactating cows, causing minimal side effects (less than 3% of induced abortions and shedding of the vaccine strain in milk).

A program based on the conjunctival vaccination of the whole population (with the exception of bulls), being repeated every two years for at least one animal generation (5 to 8 years), is the most practical, economical, and effective strategy to control the disease. As an alternative, the vaccination of the whole population the first year and then applying the exclusive vaccination of young replacement heifers in the ensuing years will also control the disease, reducing the prevalence to a minimum compatible with the further application of a testing and slaughtering eradication program.

SUITABLE IN BOTH MASS VACCINATION
AND ERADICATION PROGRAMS

Unlike the classical B-19 subcutaneous vaccine, B19 CZV OCULAR induces a very weak and short-lasting serological response, which does not interfere in the long term when applied exclusively in young replacement heifers of 3-4 months of age.

In the absence of secondary antigenic contacts, most vaccinated heifers become negative in both RBT and CFT brucellosis tests between 6 and 8 months after vaccination. Thus, this weak antibody response minimizes or even abrogates the potential interference in the conventional serological tests used in test and slaughter eradication programs.